Τρίτη 4 Απριλίου 2017

Drug combination boost PARP inhibitor response in resistant ovarian cancer

About one-third of patients with ovarian cancer who wouldn't be expected to respond to a PARP inhibitor had partial shrinkage of their tumour when a kinase inhibitor was added to treatment, report scientists from Dana-Farber Cancer Institute. "When we...

from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2nzUxQ6
via IFTTT

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου

Δημοφιλείς αναρτήσεις